UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
VITALCOM INC
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.001
- --------------------------------------------------------------------------------
(Title of Class of Securities)
927917104
- --------------------------------------------------------------------------------
(CUSIP Number)
John E. Runnells
The Vertical Group, L.P.
18 Bank Street
Summit, N.J. 07901
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 1, 2000
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box |_|.
Note: Schedules filed in proper formal shall includes 2 signed original and give
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the act (however, see the
Notes).
<PAGE>
SCHEDULE 13D
- ------------------------- --------------------------
CUSIP No. 927917104 Page 2 of 7 Pages
- ------------------------- --------------------------
- -------------------------------------------------------------------------------
1 | NAME OF REPORTING PERSON
| S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
|
| The Vertical Fund Asociates, L.P.
- -------------------------------------------------------------------------------
|
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
| (b) |_|
- --------------------------------------------------------------------------------
3 | SEC USE ONLY
|
- --------------------------------------------------------------------------------
4 | SOURCE OF FUNDS*
|
| WC
- --------------------------------------------------------------------------------
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
| TO ITEMS 2(d) OR 2(e)
| |_|
- --------------------------------------------------------------------------------
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
|
| Delaware
- --------------------------------------------------------------------------------
| 7 | SOLE VOTING POWER
| |
| | 340,682
NUMBER OF SHARES |-----|--------------------------------------
BENEFICIALLY | 8 | SHARED VOTING POWER
OWNED BY EACH | |
REPORTING PERSON | |
WITH |-----|--------------------------------------
| 9 | SOLE DISPOSITIVE POWER
| |
| | 340,682
|-----|--------------------------------------
| 10 | SHARED DISPOSITIVE POWER
| |
| |
- --------------------------------------------------------------------------------
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
| 340,682
- --------------------------------------------------------------------------------
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
| SHARES
| |_|
- --------------------------------------------------------------------------------
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
| 4.3%
- --------------------------------------------------------------------------------
14 | TYPE OF REPORTING PERSON*
|
| PN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
-2-
<PAGE>
SCHEDULE 13D
- ------------------------- --------------------------
CUSIP No. 927917104 Page 3 of 7 Pages
- ------------------------- --------------------------
- -------------------------------------------------------------------------------
1 | NAME OF REPORTING PERSON
| S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
|
| Vertical Life Sciences, L.P.
- -------------------------------------------------------------------------------
|
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
| (b) |_|
- --------------------------------------------------------------------------------
3 | SEC USE ONLY
|
- --------------------------------------------------------------------------------
4 | SOURCE OF FUNDS*
|
| WC
- --------------------------------------------------------------------------------
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
| TO ITEMS 2(d) OR 2(e)
| |_|
- --------------------------------------------------------------------------------
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
|
| Delaware
- --------------------------------------------------------------------------------
| 7 | SOLE VOTING POWER
| |
| | 71,700
NUMBER OF SHARES |-----|--------------------------------------
BENEFICIALLY | 8 | SHARED VOTING POWER
OWNED BY EACH | |
REPORTING PERSON | |
WITH |-----|--------------------------------------
| 9 | SOLE DISPOSITIVE POWER
| |
| | 71,700
|-----|--------------------------------------
| 10 | SHARED DISPOSITIVE POWER
| |
| |
- --------------------------------------------------------------------------------
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
| 71,700
- --------------------------------------------------------------------------------
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
| SHARES
| |_|
- --------------------------------------------------------------------------------
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
| 0.9%
- --------------------------------------------------------------------------------
14 | TYPE OF REPORTING PERSON*
|
| PN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
-3-
<PAGE>
SCHEDULE 13D
- ------------------------- --------------------------
CUSIP No. 927917104 Page 4 of 7 Pages
- ------------------------- --------------------------
- -------------------------------------------------------------------------------
1 | NAME OF REPORTING PERSON
| S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
|
| Stephen D. Baksa
- -------------------------------------------------------------------------------
|
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
| (b) |_|
- --------------------------------------------------------------------------------
3 | SEC USE ONLY
|
- --------------------------------------------------------------------------------
4 | SOURCE OF FUNDS*
|
| PF
- --------------------------------------------------------------------------------
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
| TO ITEMS 2(d) OR 2(e)
| |_|
- --------------------------------------------------------------------------------
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
|
| Delaware
- --------------------------------------------------------------------------------
| 7 | SOLE VOTING POWER
| |
| | 19,500
NUMBER OF SHARES |-----|--------------------------------------
BENEFICIALLY | 8 | SHARED VOTING POWER
OWNED BY EACH | |
REPORTING PERSON | | 412,382
WITH |-----|--------------------------------------
| 9 | SOLE DISPOSITIVE POWER
| |
| | 19,500
|-----|--------------------------------------
| 10 | SHARED DISPOSITIVE POWER
| |
| | 412,382
- --------------------------------------------------------------------------------
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
| 431,882
- --------------------------------------------------------------------------------
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
| SHARES
| |_|
- --------------------------------------------------------------------------------
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
| 5.5%
- --------------------------------------------------------------------------------
14 | TYPE OF REPORTING PERSON*
|
| IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
-4-
<PAGE>
This Amendment No. 3 to Statement on Schedule 13-D ("Statement") with
respect to the Common Stock, par value $0.001 per share, of VitalCom Inc. (the
"Issuer") is filed jointly by Vertical Fund Associates, L.P. ("Associates") and
Vertical Life Sciences, L.P. ("Life Sciences")(collectively, the "Partnerships")
and Stephen D. Baksa ("Baksa")(the "Partnerships and Baksa are hereinafter
sometimes referred to collectively as the "Reporting Persons") in order to amend
Items 3 and 5 of the Statement (as heretofore amended) to read in their entirety
as set forth below. No change is made to the other Items contained in the
Statement.
Item 3. Source and Amount of Funds or Other Consideration.
As of the close of business on March 1, 2000, Associates owned 340,682
shares of VCOM Common Stock, which it acquired at an aggregate cost of
$1,633,469; Life Sciences owned 71,700 shares of VCOM Common Stock, which it
acquired at an aggregate cost of $161,325; and Baksa owned 19,500 shares of VCOM
Common Stock, which he acquired at aggregate cost of $93,406. All of the 431,882
shares of VCOM Common Stock collectively owned by the Reporting Persons are
hereinafter referred to as the "Shares". The source of funds used by each
Partnership to acquire the Shares owned by it was such Partnership's internal
cash funds. The source of funds used by Baksa to acquire the shares owned by him
was his personal funds.
Item 5. Interest in Securities of the Issuer.
(a) and (b) Of the total Shares beneficially owned by the Reporting
Persons, 340,682 shares (approximately 4.3% of the total outstanding) are
directly and beneficially owned by Associates; 71,700 shares (approximately 0.9%
of the total outstanding) are directly and beneficially owned by Life Sciences;
and 19,500 shares (approximately 0.2% of the total outstanding) are directly and
beneficially owned by Baksa. Subject to the next succeeding paragraph, each of
the Reporting Persons has the sole power to vote or direct the vote and to
dispose or direct the disposition of the Shares directly and beneficially owned
by such Reporting Person.
In addition, Group may be deemed to be the beneficial owner of all 412,382
Shares (approximately 5.2% of the total outstanding) collectively owned by the
two Partnerships because, as the sole general partner of both Partnerships,
Group has the sole power to vote or direct the vote and to dispose or direct
-5-
<PAGE>
the disposition of such Shares, and each of the Individuals (including Baksa)
may be deemed to be the beneficial owner of all 412,382 Shares (approximately
5.2% of the total outstanding) collectively owned by the two Partnerships
because as a general partner of Group (which is the sole general partner of both
Partnerships), each such Individual shares the power (which may be exercised by
any one of such Individuals acting alone) to vote or direct the vote and to
dispose or direct the disposition of such Shares.
(c) The chart below lists all transactions in VCOM Common Stock during the
60 days ended March 1, 2000 by any of the persons identified in response to
paragraph (a) of this Item 5, all of which transactions were sales effected in
the open market:
Person
Effecting Date of Number of Price per
Transaction Transaction Shares Share
- ----------- ----------------- --------- ---------
Associates February 11, 2000 59,750 $5.04
Life Sciences February 11, 2000 59,750 $5.04
Associates February 14, 2000 33,650 $5.35
Life Sciences February 14, 2000 33,650 $5.35
Associates February 15, 2000 1,500 $5.25
Life Sciences February 15, 2000 1,500 $5.25
Associates February 16, 2000 12,400 $5.00
Life Sciences February 16, 2000 12,400 $5.00
Associates February 18, 2000 2,600 $4.88
Life Sciences February 18, 2000 2,600 $4.88
Associates February 29, 2000 9,000 $4.50
Life Sciences February 29, 2000 8,000 $4.50
Associates March 1, 2000 80,000 $5.50
Life Sciences March 1, 2000 26,600 $5.50
(d) and (e) Not applicable.
-6-
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of their knowledge and belief, the
undersigned certify that the information set forth in this Statement is true,
complete and correct.
March 2, 2000 VERTICAL FUND ASSOCIATES, L.P.
BY: THE VERTICAL GROUP, L.P.
General Partner
By: /s/ John E. Runnells
------------------------------
John E. Runnells
General Partner
VERTICAL LIFE SCIENCES, L.P.
BY: THE VERTICAL GROUP, L.P.
General Partner
By: /s/ John E. Runnells
------------------------------
John E. Runnells
General Partner
/s/ Stephen D. Baksa
------------------------------
Stephen D. Baksa
-7-
